- Record: found
- Abstract: found
- Article: not found
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
Jan B Vermorken
1 ,
José Trigo ,
Ricardo Hitt ,
Piotr Koralewski ,
Eduardo Diaz-Rubio ,
Frédéric Rolland ,
Rainald Knecht ,
Nadia Amellal ,
Armin Schueler ,
José Baselga
Jun 01 2007
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
To evaluate the efficacy and safety of the epidermal growth factor receptor-directed monoclonal antibody cetuximab administered as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) who experience disease progression on platinum therapy.